Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors. Issue 22 (15th November 2016)

• Record Type: Journal Article
• Authors: Wurz, Ryan P.; Sastri, Christine; D'Amico, Derin C.; Herberich, Brad; Jackson, Claire L.M.; Pettus, Liping H.; Tasker, Andrew S.; Wu, Bin; Guerrero, Nadia; Lipford, J. Russell; Winston, Jeffrey T.; Yang, Yajing; Wang, Paul; Nguyen, Yen; Andrews, Kristin L.; Huang, Xin; Lee, Matthew R.; Mohr, Christopher; Zhang, J.D.; Reid, Darren L.; Xu, Yang; Zhou, Yihong; Wang, Hui-Ling
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 26:Issue 22(2016)
• Page Start: 5580
• Page End: 5590
• Publication Date: 2016-11-15
• Subjects: Pim kinase -- Kinase inhibitor -- Oncology -- Proliferation -- Hematologic cancer -- Multiple myeloma; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2016.09.067
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit ( rac -1 ) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50 values of 0.024 nM and 0.095 nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50 = 28 nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.